Latest News for: hikma

Edit

Investing in manufacturing excellence at Hikma (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
Our purpose in action Manufacturing excellence sits at the heart of Hikma's operations ... "Manufacturing excellence is the foundation of everything we do at Hikma ... Hikma Pharmaceuticals plc published ...
Edit

2025 Annual Report and Accounts (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
Hikma Pharmaceuticals plc published this content on March 18, 2026, and is solely ...
Edit

Investing in R&D to drive high-value pipeline delivery (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
Our purpose in action Hikma is committed to building a differentiated pipeline of complex products ... Hikma Pharmaceuticals plc published this content on March 18, 2026, and is solely responsible for the information contained herein.
Edit

Investing in strategic partnerships driving growth in the US and MENA (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
In 2025, we accelerated growth through targeted partnerships, leveraging the complementary strengths of Hikma and our partners to achieve faster regulatory approvals, expanded market access, and portfolio expansion ... For Hikma.
Edit

Investing in the development of our people for long‑term growth (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
Building strong leaders at every level remains central to Hikma's strategy ... This initiative strengthens collaboration, accelerates knowledge transfer, and helps our colleagues shape long-term careers at Hikma.
Edit

Investing in MENA to expand access and drive growth (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
In the MENA region, where we leverage our global expertise locally, Hikma is the largest pharmaceutical company by sales1 ... "Hikma is the trusted partner of choice in MENA ... Hikma Pharmaceuticals plc ...
Edit

AGM 2026 Notice (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
© Hikma Pharmaceuticals PLC ... Joined Hikma ... Joined Hikma ... Joined Hikma ... Joined Hikma ... Ali joined Hikma as Director of Hikma Pharma Limited and held various management and leadership roles within the Group before stepping into an advisory role in 1995.
Edit

Notice of 2026 Annual General Meeting (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
© Hikma Pharmaceuticals PLC ... Joined Hikma ... Joined Hikma ... Joined Hikma ... Joined Hikma ... Ali joined Hikma as Director of Hikma Pharma Limited and held various management and leadership roles within the Group before stepping into an advisory role in 1995.
Edit

Annual Report 2025 (Hikma Pharmaceuticals plc)

Public Technologies 18 Mar 2026
© Hikma Pharmaceuticals PLC ... Hikma puts better health within reach, every day ... Sustainability at Hikma 42 ... Hikma Rx 34 ... Merkuba Erceg is a Senior Lab Technician at Hikma's Zagreb R&D hub ... Hikma Rx1 ... Hikma Rx ... Hikma Rx ... 2 Hikma Pharmaceuticals PLC .
Edit

Hikma R&D. Innovation in formulation development. Meet Hamza Qassim (Hikma Pharmaceuticals plc)

Public Technologies 11 Mar 2026
Discover what it's like to work at Hikma through our employee testimonials ... How would you describe working at Hikma?. Working at Hikma is a challenging, empowering, and growth oriented. Hikma provides a ...
Edit

Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US (Hikma Pharmaceuticals plc)

Public Technologies 11 Mar 2026
London, 11 March 2026 - Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (Hikma) announces it has launched an authorised generic version of Nucynta® ER (tapentadol) extended-release for US patients.
Edit

Full year 2025 results Q&A transcript (Hikma Pharmaceuticals plc)

Public Technologies 27 Feb 2026
Hikma Pharmaceuticals plc published this content on February 27, 2026, and is ...
Edit

Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes

Al Bawaba 27 Feb 2026
Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational ...
Edit

Hikma shares drop 17% on weaker forecasts and scrapped guidance

The Times/The Sunday Times 26 Feb 2026
The FTSE 100 ...
Edit

Hikma Posts 7% Revenue Rise at $3.349bln in 2025

Petra 26 Feb 2026
26 (Petra) -- Hikma Pharmaceuticals reported audited financial results for the year ending Dec ... performance in branded medicines and "Hikma Rx", alongside improved performance in the generics segment.

Article Search

tools
×
×
×
×